ストックスクリーナーアプリを入手
3.03
0.33%
0.010
アフターアワーズ：
3.03
Genelux Corp (GNLX) 最新ニュース
Genelux head of regulatory Ralph Smalling sells $562 in stock By Investing.com - Investing.com India
Tax-related share sale by Genelux (GNLX) Head of Regulatory - Stock Titan
Genelux head of regulatory Ralph Smalling sells $562 in stock - Investing.com
Genelux director Thomas John sold $29,801 in company stock By Investing.com - Investing.com India
Insider Sell: John Thomas Sells 10,000 Shares of Genelux Corp (G - GuruFocus
Genelux director Thomas John sold $29,801 in company stock - Investing.com
GENELUX (NASDAQ: GNLX) director sells 10,000 shares in Rule 10b5-1 trade - Stock Titan
Genelux Corp. Financial Disclosures & SEC Filings - TradingView
GNLX (NASDAQ) director sells 10,000 shares via 10b5-1, $28,957 proceeds - Stock Titan
GNLX Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Development Stage; Stock Edges HigherAnnual Earnings Summary - newsline.com
GNLX Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEarnings Surprise Stocks - newsline.com
GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
GNLX Technical Analysis | Trend, Signals & Chart Patterns | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Genelux president and CEO Zindrick Thomas sells $8,225 in stock By Investing.com - Investing.com Nigeria
Genelux CSO Yu Yong sells $1,798 of common stock - Investing.com UK
Genelux CSO Yu Yong sells $1,798 of common stock By Investing.com - Investing.com Nigeria
Genelux CTO Joseph Cappello sells $1,799 in company stock By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $804 in stock By Investing.com - Investing.com Nigeria
Genelux president and CEO Zindrick Thomas sells $8,225 in stock - Investing.com
Genelux CTO Joseph Cappello sells $1,799 in company stock - Investing.com
Genelux head of regulatory sells $804 in stock - Investing.com
Genelux (GNLX) CSO Yu Yong sells 605 shares to cover RSU tax bill - Stock Titan
Research Analysts Offer Predictions for Genelux Q2 Earnings - MarketBeat
Buy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained - TipRanks
Genelux : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Ovarian cancer trial readout due in 2H26 as Genelux cash lasts to 1Q27 - Stock Titan
GENELUX Corp 1Q 2026: Revenue $0 Net loss $8.9M, EPS $(0.20) — 10-Q Summary - TradingView
Genelux (GNLX) raises $18.5M, extends cash runway into 2027 - Stock Titan
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates - Yahoo Finance
GNLX Stock Price, Quote & Chart | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Genelux Corp expected to post a loss of 18 cents a shareEarnings Preview - TradingView
[ARS] GENELUX Corp SEC Filing - Stock Titan
Genelux (NASDAQ: GNLX) details 2026 virtual meeting, board and auditor votes - Stock Titan
Genelux (GNLX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Olvi Vec could reshape advanced ovarian cancer treatment, Genelux claims - Traders Union
Genelux Corporation (GNLX) Stock: Technical Signals (Technical Weakness) 2026-04-20Live Trade Sharing - Newser
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):